Meeting
2022 ASCO Gastrointestinal Cancers Symposium
KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation.
Authors
Tanios S. Bekaii-Saab
Division of Hematology/Oncology, Mayo Clinic, Phoenix, AZ
Tanios S. Bekaii-Saab , Alexander I. Spira , Rona Yaeger , Gary L Buchschacher Jr., Autumn Jackson McRee , Joshua K. Sabari , Melissa Lynne Johnson , Minal A. Barve , Navid Hafez , Karen Velastegui , James G Christensen , Thian Kheoh , Hirak Der-Torossian , Igor I. Rybkin
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03785249
DOI
10.1200/JCO.2022.40.4_suppl.519
Abstract #
519
Poster Bd #
M2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Safety and efficacy of D-1553 in KRAS G12C-mutated colorectal cancer: Results from a phase I/II study.
First Author: Dan-yun Ruan
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A phase 1b/2 study of VS-6766 in combination cetuximab in patients (pts) with advanced KRAS mt colorectal cancer (CRC).
First Author: Ardaman Shergill
Poster
2024 ASCO Gastrointestinal Cancers Symposium
KRAS mutation status in the prediction of pancreatic tumor response after neoadjuvant systemic therapy and magnetic resonance-guided SBRT.
First Author: Amit Jethanandani
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
First Author: Evan Justin Walker